Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Certolizumab + Nivolumab + Chemotherapy in Resectable Stage II-III Lung Cancer
NCT04991025Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Oct 2022
- Primary completion
- Oct 2026
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of certolizumab pegol in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Started Oct 2022; status: recruiting.
02
Drugs
certolizumab pegol
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04991025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991025.